The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma

Pancreatic cancer is the third leading cause of cancer-related deaths, characterised by poor survival, marked molecular heterogeneity and high intrinsic and acquired chemoresistance. Only 10⁻20% of pancreatic cancer patients present with surgically resectable disease and even then, 80% die within 5...

Full description

Saved in:
Bibliographic Details
Published in:Diseases 2018-11, Vol.6 (4), p.103
Main Authors: Parkin, Ashleigh, Man, Jennifer, Chou, Angela, Nagrial, Adnan M, Samra, Jaswinder, Gill, Anthony J, Timpson, Paul, Pajic, Marina
Format: Article
Language:English
Subjects:
Abdomen
Adenocarcinoma
Biomarkers
Cancer therapies
Cell cycle
Chemoresistance
Clinical trials
Gene expression
Genomics
Lymphatic system
Malignancy
Medical prognosis
Metastasis
molecular classification
Mutation
Pain
Pancreatic cancer
Patients
Precision medicine
Review
tailored therapy
Tumors
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic cancer is the third leading cause of cancer-related deaths, characterised by poor survival, marked molecular heterogeneity and high intrinsic and acquired chemoresistance. Only 10⁻20% of pancreatic cancer patients present with surgically resectable disease and even then, 80% die within 5 years. Our increasing understanding of the genomic heterogeneity of cancer suggests that the failure of definitive clinical trials to demonstrate efficacy in the majority of cases is likely due to the low proportion of responsive molecular subtypes. As a consequence, novel treatment strategies to approach this disease are urgently needed. Significant developments in the field of precision oncology have led to increasing molecular stratification of cancers into subtypes, where individual cancers are selected for optimal therapy depending on their molecular or genomic fingerprint. This review provides an overview of the current status of clinically used and emerging treatment strategies, and discusses the advances in and the potential for the implementation of precision medicine in this highly lethal malignancy, for which there are currently no curative systemic therapies.
ISSN:2079-9721
2079-9721
DOI:10.3390/diseases6040103